Evidence map›Paper›PMID 35006412›Full record

ArticleEJNMMI research2022

Whole-body biodistribution and radiation dosimetry of [

Wencke Lehnert, Patrick J Riss, Ana Hurtado de Mendoza, Sandra Lopez, Gonzalo Fernandez, Marcelo Ilheu, Horacio Amaral, Vasko Kramer

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Preclinical evaluation of [EJNMMI research · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Wencke LehnertDepartment of Nuclear Medicine, University Medical Center Hamburg, Hamburg, Germany.
Patrick J RissDepartment of Chemistry, University of Oslo, Oslo, Norway.
Ana Hurtado de MendozaCenter for Nuclear Medicine and PET/CT Positronmed, 7501068, Providencia, Santiago, Chile.
Sandra LopezCenter for Nuclear Medicine and PET/CT Positronmed, 7501068, Providencia, Santiago, Chile.
Gonzalo FernandezCenter for Nuclear Medicine and PET/CT Positronmed, 7501068, Providencia, Santiago, Chile.
Marcelo IlheuPositronpharma SA, Rancagua 878, 7500921, Providencia, Santiago, Chile.
Horacio AmaralCenter for Nuclear Medicine and PET/CT Positronmed, 7501068, Providencia, Santiago, Chile.
Vasko KramerCenter for Nuclear Medicine and PET/CT Positronmed, 7501068, Providencia, Santiago, Chile. vkramer@positronpharma.cl.ORCID http://orcid.org/0000-0002-5285-6447
Itron (United States) · USUniversität Hamburg · DEUniversity of Oslo · NO

Funding

innovachile, corfo 13PIE-21682
6 · The paper itself

Abstract

purpose[

methodsSix healthy subjects (n = 3 males, n = 3 females) were enrolled in this study. A series of 14 whole-body PET/CT scans were acquired until 5.5 h post-injection of 200 ± 11 MBq of [

resultsPhysiological uptake of [

conclusion[

Indexed as

[18F]PR04.MZDopamine transporterDosimetryParkinson’s diseasePositron emission tomography

Identifiers

PMID35006412
PMCPMC8748605
OpenAlexW4206569942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.